Gubra A/S raised financial guidance for full-year 2023. For the period, organic revenue growth is now expected to be 16-21% (previously around 10%).
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
305 DKK | -9.76% | -1.29% | +144.00% |
Apr. 17 | Gubra Unveils UCN2 as Novel Anti-Obesity Drug Candidate for Healthy Weight Loss | CI |
Mar. 29 | Certain Shares of Gubra A/S are subject to a Lock-Up Agreement Ending on 29-MAR-2024. | CI |
1st Jan change | Capi. | |
---|---|---|
+144.00% | 795M | |
+4.82% | 109B | |
+11.36% | 105B | |
-0.38% | 22.25B | |
-12.37% | 22.09B | |
-7.66% | 18.68B | |
-36.52% | 17.58B | |
-9.85% | 16.85B | |
+4.57% | 13.76B | |
+34.70% | 12.46B |
- Stock Market
- Equities
- GUBRA Stock
- News Gubra A/S
- Gubra A/S Raises Financial Guidance for Full-Year 2023